1.76
+0.145(+9.01%)
Currency In USD
| Previous Close | 1.61 |
| Open | 1.63 |
| Day High | 1.76 |
| Day Low | 1.63 |
| 52-Week High | 5.2 |
| 52-Week Low | 1.26 |
| Volume | 159,878 |
| Average Volume | 834,764 |
| Market Cap | 187.09M |
| PE | -4.18 |
| EPS | -0.42 |
| Moving Average 50 Days | 1.5 |
| Moving Average 200 Days | 2.62 |
| Change | 0.14 |
If you invested $1000 in MaxCyte, Inc. (MXCT) since IPO date, it would be worth $103.24 as of October 20, 2025 at a share price of $1.755. Whereas If you bought $1000 worth of MaxCyte, Inc. (MXCT) shares 3 years ago, it would be worth $305.22 as of October 20, 2025 at a share price of $1.755.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
GlobeNewswire Inc.
Oct 08, 2025 12:05 PM GMT
ROCKVILLE, Md., Oct. 08, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cel
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
GlobeNewswire Inc.
Oct 06, 2025 12:05 PM GMT
MaxCyte’s Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio’s engineered T cell therapiesROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
GlobeNewswire Inc.
Sep 22, 2025 8:30 PM GMT
ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation ce